Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) EBITDA (2016 - 2025)

Historic EBITDA for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $388.5 million.

  • United Therapeutics' EBITDA rose 1323.23% to $388.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 1673.44%. This contributed to the annual value of $1.4 billion for FY2024, which is 1621.23% up from last year.
  • Per United Therapeutics' latest filing, its EBITDA stood at $388.5 million for Q3 2025, which was up 1323.23% from $364.5 million recorded in Q2 2025.
  • United Therapeutics' 5-year EBITDA high stood at $388.5 million for Q3 2025, and its period low was -$64.8 million during Q1 2021.
  • Its 5-year average for EBITDA is $275.4 million, with a median of $313.4 million in 2023.
  • As far as peak fluctuations go, United Therapeutics' EBITDA plummeted by 13887.22% in 2021, and later skyrocketed by 54444.44% in 2022.
  • United Therapeutics' EBITDA (Quarter) stood at $169.8 million in 2021, then grew by 3.42% to $175.6 million in 2022, then skyrocketed by 48.12% to $260.1 million in 2023, then skyrocketed by 37.52% to $357.7 million in 2024, then grew by 8.61% to $388.5 million in 2025.
  • Its EBITDA stands at $388.5 million for Q3 2025, versus $364.5 million for Q2 2025 and $382.8 million for Q1 2025.